June 1, 2020, Essex Junction, VT – Haematologic Technologies (HTI), a leading provider of products and analytical services supporting the research, development, and commercialization of large molecule biotherapeutics, today announced that Jean Pineault has been appointed President & CEO. Jean is a seasoned Life Sciences executive with significant experience in the Healthcare, Biotech, and Pharmaceutical industries specializing in contract research organizations (CRO) and clinical diagnostics. Over his career, he spearheaded multiple laboratory and manufacturing business transformations in organizations focused in both small and large molecule biotherapeutics.
“Haematologic Technologies has a powerful combination of capabilities whereby scientific expertise is leveraged in a focused and unique combination of offerings for the biologics testing and development industries. Additionally, HTI is engaged in providing services that are directly linked to COVID-19 treatment. The natural culture of HTI is exceptional, where employees excel in connecting science with customer service in a stringent multifaceted regulatory environment. I am excited at the opportunity and privilege to lead such a great company,” said Jean Pineault.
“Jean’s energy, passion, and a rare combination of commercial and operational expertise will accelerate HTI’s transformation into the leading provider of large molecule bioanalytical services,” said Brian Scanlan, Chairman of the Board of Directors.
Jean succeeds Rick Jenny who will remain engaged with HTI in a scientific advisory role. “When I began my HTI journey 31 years ago, my vision was to create a world-class company to serve the pharma and research communities by combining scientific expertise and business acumen. The opportunity presented under the leadership of Mr. Pineault is progressive – exciting – and I look forward to my new role as a scientific adviser on the Medical and Scientific Advisory Board where I will continue to foster a culture steeped in scientific excellence and strong customer service,” said Dr. Richard Jenny.
HTI boasts deep expertise in protein chemistry with an analytical service offering comprised of protein and other large molecule characterization, highly advanced assay development in GLP and CLIA environments, coagulation and analytical research reagents, including purified proteins, inhibitors and substrates, antibodies, and deficient plasma products for both research and IVD/POC applications and GMP release testing. HTI’s service and technology offering is focused in the areas of immune-assays, anti-drug antibody testing, thrombin generation assays, assessment of hemostatic risk, host cell protein mitigation, stability, and release testing, as well as a variety of other specialized assays for biotherapeutics supporting discovery through commercial release.
Edgewater Capital Partners acquired HTI on October 11, 2019. Please see the press release here: https://www.haemtech.com/blog/exciting-news-haemtech-acquired/
About Haematologic Technologies:
Haematologic Technologies is the leading provider of products and analytical services to support the research, development, and commercialization of large molecule biotherapeutics. HTI has deep expertise in protein biochemistry including characterization of plasma proteins and other large molecules, and performs highly advanced assay development and GMP testing in the areas of immunoassays, thrombin generation assays, assessment of hemostatic risk, anti-drug antibody testing (immunogenicity), host cell protein mitigation, stability and release testing, as well as a variety of other specialized assays for biotherapeutics supporting discovery through commercial release. The company’s biopharma services are performed in fully compliant, FDA-inspected GMP facilities.
Building on its 30+ years of expertise in plasma proteins, hemostasis, and blood coagulation, HTI is also a leading global supplier of coagulation research reagents (plasma proteins and antibodies), custom formulated IVD/POC device reagents, and customized blood collection tubes for clinical trials. Visit us at www.haemtech.com.
About Edgewater Capital Partners
Edgewater Capital Partners is a Cleveland-based private equity firm with a difference. A Deep Sector Expertise in Specialty Industrials, Life Science, Advanced Materials, and Specialty Chemicals enables accelerated diligence, certainty to close, and real value creation post-transaction. We espouse a Growth Enabling Philosophy, with thoughtful, but prudent investment in people, infrastructure, and technology to unlock the true potential of our portfolio companies. And Edgewater is not traditional private equity; our attitude is different. We call it Midwestern Values – honesty, integrity, and transparency. We bring an attitude of humility that builds an environment of trust and collaboration. This is particularly important in the lower middle market where we play. Nearly half of our transactions are owner-operator situations where the owners have built their company from scratch, and cultural fit with an investment partner is fundamental. The result is a full alignment of interests and culture making Edgewater a successful steward of the companies we invest in. Visit us at www.edgewatercapital.com.